HBR

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Spero Therapeutics, Inc. (SPRO)

Retrieved on: 
Thursday, June 9, 2022
Legal, Professional Services, New Drug Application, Time, Company, HBR, Food, Court, News, Workforce, Therapy, FDA, Defendant, Review, GPM, NASDAQ, Tebipenem, Urinary tract infection, Lists of schools in England, NDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Suite, Medical device, Pharmaceutical industry, Spero

Glancy Prongay & Murray LLP (GPM) reminds investors of the upcoming July 25, 2022 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Spero Therapeutics, Inc. (Spero or the Company) (NASDAQ: SPRO ) securities between October 28, 2021 and May 2, 2022, inclusive (the Class Period).

Key Points: 
  • Glancy Prongay & Murray LLP (GPM) reminds investors of the upcoming July 25, 2022 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Spero Therapeutics, Inc. (Spero or the Company) (NASDAQ: SPRO ) securities between October 28, 2021 and May 2, 2022, inclusive (the Class Period).
  • You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.
  • On this news, Speros stock fell $1.59, or 18.27%, to close at $7.11 per share on April 1, 2022.
  • To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.

Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Spero Therapeutics, Inc. (SPRO)

Retrieved on: 
Wednesday, June 8, 2022
Legal, Professional Services, New Drug Application, Time, Company, HBR, Food, Court, News, Telephone, Workforce, Therapy, FDA, Defendant, Review, NASDAQ, Law, Tebipenem, Urinary tract infection, Lists of schools in England, NDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Suite, Security (finance), Pharmaceutical industry, Spero

Investors suffering losses on their Spero investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 888-638-4847 or by email to [email protected] .

Key Points: 
  • Investors suffering losses on their Spero investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 888-638-4847 or by email to [email protected] .
  • On this news, Speros stock fell $1.59, or 18.27%, to close at $7.11 per share on April 1, 2022.
  • To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Spero Therapeutics, Inc. (SPRO) Investors

Retrieved on: 
Tuesday, June 7, 2022
Legal, Professional Services, New Drug Application, Time, Company, HBR, Food, Court, News, Workforce, Therapy, FDA, Defendant, Review, GPM, NASDAQ, Tebipenem, Urinary tract infection, Lists of schools in England, NDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Suite, Medical device, Pharmaceutical industry, Spero

Spero investors have until July 25, 2022 to file a lead plaintiff motion.

Key Points: 
  • Spero investors have until July 25, 2022 to file a lead plaintiff motion.
  • You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.
  • On this news, Speros stock fell $1.59, or 18.27%, to close at $7.11 per share on April 1, 2022.
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

H+M Industrial EPC Named Best in Class at 35th Annual Houston Safety Excellence Awards

Retrieved on: 
Tuesday, June 7, 2022
EPC, Texas International Airlines, Accident, HASC, HBR, CEO, National Safety Council, Gulf Coast of the United States, Injury, Energy, Greater Houston, Kuraray, Industry, Efficiency, TPC, Health, Construction, Safety

PASADENA, Texas, June 7, 2022 /PRNewswire/ -- H+M Industrial EPC , headquartered in Pasadena, TX, was awarded "Best in Class" for the category General Contractor Small at the 35th Annual Houston Safety Excellence Awards on May 20, 2022.

Key Points: 
  • PASADENA, Texas, June 7, 2022 /PRNewswire/ -- H+M Industrial EPC , headquartered in Pasadena, TX, was awarded "Best in Class" for the category General Contractor Small at the 35th Annual Houston Safety Excellence Awards on May 20, 2022.
  • The Houston Business Roundtable and the Health and Safety Council recognize companies in the Greater Houston Area for outstanding safety performance through HBR's audit process and the banquet co-hosted with HASC.
  • "With a mantra of 'Inspiring a Lifestyle of Safety,' we encourage safety in all daily activities to all our employees.
  • About H+M Industrial EPC: H+M Industrial EPC has provided design/build services to the Energy and Chemicals industries along the Gulf Coast since 1988.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Twitter, LMP, and Spero and Encourages Investors to Contact the Firm

Retrieved on: 
Saturday, June 4, 2022
New Drug Application, Mission statement, Company, HBR, Ownership, Infection, Food, Annual report, Income, Complicated, News, Treatment, Lists of schools in England, Workforce, FDA, GLOBE, Patient, Defendant, TWTR, Review, Musk, Spero, NYSE, Urinary tract infection, Tebipenem, NASDAQ, SEC, Population, LMP, NDA, Degenerative disease, U.S. Securities and Exchange Commission, Disclosure, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Documentation, Relevant, Complaint, Cryptocurrency, Audit, Medical device, Renewable energy, Pharmaceutical industry, Forbes, Twitter, Pyelonephritis, P.C

By failing to timely disclose his ownership stake, Musk was able to acquire shares of Twitter less expensively during the Class Period.

Key Points: 
  • By failing to timely disclose his ownership stake, Musk was able to acquire shares of Twitter less expensively during the Class Period.
  • On March 31, 2022, Spero issued a press release announcing the Companys fourth quarter and full year 2021 financial results.
  • For more information on the Spero class action go to: https://bespc.com/cases/SPRO
    About Bragar Eagel & Squire, P.C.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Spero Therapeutics, Inc. (SPRO) Investors

Retrieved on: 
Monday, June 6, 2022
Legal, Professional Services, New Drug Application, Time, Company, HBR, Food, Court, News, Workforce, Therapy, FDA, Defendant, Review, Spero, NASDAQ, Twitter, Law, Tebipenem, Urinary tract infection, Lists of schools in England, NDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Person, Suite, Pharmaceutical industry

The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of persons and entities that purchased or otherwise acquired Spero Therapeutics, Inc. (Spero or the Company) (NASDAQ: SPRO ) securities between October 28, 2021 and May 2, 2022, inclusive (the Class Period).

Key Points: 
  • The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of persons and entities that purchased or otherwise acquired Spero Therapeutics, Inc. (Spero or the Company) (NASDAQ: SPRO ) securities between October 28, 2021 and May 2, 2022, inclusive (the Class Period).
  • Spero investors have until July 25, 2022 to file a lead plaintiff motion.
  • On this news, Speros stock fell $1.59, or 18.27%, to close at $7.11 per share on April 1, 2022.
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Spero Therapeutics, Inc. (SPRO) Investors

Retrieved on: 
Monday, June 6, 2022
Legal, Professional Services, New Drug Application, Company, HBR, Food, News, Telephone, Workforce, Therapy, FDA, Defendant, Review, Spero, NASDAQ, Law, Tebipenem, Urinary tract infection, Lists of schools in England, NDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Suite, Security (finance), Pharmaceutical industry

Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Spero Therapeutics, Inc. (Spero or the Company) (NASDAQ: SPRO ) securities between October 28, 2021 and May 2, 2022, inclusive (the Class Period).

Key Points: 
  • Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Spero Therapeutics, Inc. (Spero or the Company) (NASDAQ: SPRO ) securities between October 28, 2021 and May 2, 2022, inclusive (the Class Period).
  • Spero investors have until July 25, 2022 to file a lead plaintiff motion.
  • Investors suffering losses on their Spero investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 888-638-4847 or by email to [email protected] .
  • On this news, Speros stock fell $1.59, or 18.27%, to close at $7.11 per share on April 1, 2022.

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Spero Therapeutics, Inc. (SPRO) on Behalf of Investors

Retrieved on: 
Friday, June 3, 2022
Legal, Professional Services, New Drug Application, DOJ, Company, Insurance, Program, HBR, Food, Financial Times, News, Press, Real estate investment trust, Workforce, The Wall Street Journal, FDA, Publication, Person, Review, Spero, Associated Press, Bloomberg Businessweek, SCAS, GPM, NASDAQ, SEC, Industry, Urinary tract infection, NDA, Information technology, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, LLP, Medical device, Pharmaceutical industry, Reuters, Forbes

Glancy Prongay & Murray LLP (GPM), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Spero Therapeutics, Inc. (Spero or the Company) (NASDAQ: SPRO ) investors concerning the Companys possible violations of the federal securities laws.

Key Points: 
  • Glancy Prongay & Murray LLP (GPM), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Spero Therapeutics, Inc. (Spero or the Company) (NASDAQ: SPRO ) investors concerning the Companys possible violations of the federal securities laws.
  • On this news, Speros stock fell $1.59, or 18.27%, to close at $7.11 per share on April 1, 2022.
  • Glancy Prongay & Murray LLP is a premier law firm representing investors and consumers in securities litigation and other complex class action litigation.
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Spero Therapeutics, Inc. (SPRO) on Behalf of Investors

Retrieved on: 
Friday, June 3, 2022
Legal, Professional Services, New Drug Application, Company, HBR, Food, News, Telephone, Workforce, FDA, Review, Spero, NASDAQ, Urinary tract infection, NDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Suite, Pharmaceutical industry

Law Offices of Howard G. Smith announces an investigation on behalf of Spero Therapeutics, Inc. (Spero or the Company) (NASDAQ: SPRO ) investors concerning the Companys possible violations of federal securities laws.

Key Points: 
  • Law Offices of Howard G. Smith announces an investigation on behalf of Spero Therapeutics, Inc. (Spero or the Company) (NASDAQ: SPRO ) investors concerning the Companys possible violations of federal securities laws.
  • On this news, Speros stock fell $1.59, or 18.27%, to close at $7.11 per share on April 1, 2022.
  • On this news, Speros stock fell $3.25, or 63.65%, to close at $1.85 per share on May 3, 2022, thereby injuring investors further.
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

The Law Offices of Frank R. Cruz Announces Investigation of Spero Therapeutics, Inc. (SPRO) on Behalf of Investors

Retrieved on: 
Thursday, June 2, 2022
Legal, Professional Services, New Drug Application, Company, HBR, Food, News, Workforce, Therapy, FDA, Review, Spero, NASDAQ, Twitter, Law, Urinary tract infection, NDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Suite, Pharmaceutical industry

The Law Offices of Frank R. Cruz announces an investigation of Spero Therapeutics, Inc. (Spero or the Company) (NASDAQ: SPRO ) on behalf of investors concerning the Companys possible violations of federal securities laws.

Key Points: 
  • The Law Offices of Frank R. Cruz announces an investigation of Spero Therapeutics, Inc. (Spero or the Company) (NASDAQ: SPRO ) on behalf of investors concerning the Companys possible violations of federal securities laws.
  • On this news, Speros stock fell $1.59, or 18.27%, to close at $7.11 per share on April 1, 2022.
  • On this news, Speros stock fell $3.25, or 63.65%, to close at $1.85 per share on May 3, 2022, thereby injuring investors further.
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.